The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.

Atıf İçin Kopyala

Ak M. A., Sahip B., Geduk A., Ucar M. A., Kale H., Hacibekiroglu T., ...Daha Fazla

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, cilt.38, sa.2, ss.299-308, 2022 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 38 Sayı: 2
• Basım Tarihi: 2022
• Doi Numarası: 10.1007/s12288-021-01458-1
• Dergi Adı: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE
• Sayfa Sayıları: ss.299-308
• Anahtar Kelimeler: Myelodysplastic syndrome, Low-risk-intermediate-1-risk, Epoetin alfa, Darbepoetin alfa, Treatment response
• Çukurova Üniversitesi Adresli: Evet